Influenza epidemiology in patients admitted to sentinel Australian hospitals in 2019: the Influenza Complications Alert Network (FluCAN)
DOI:
https://doi.org/10.33321/cdi.2022.46.14Keywords:
influenza, public health surveillance, influenza vaccines, vaccination coverage, vaccine effectivenessAbstract
Influenza is a common cause of acute respiratory infection, and is a major cause of morbidity and mortality. This report summarises the epidemiology of hospitalisations with laboratory-confirmed influenza during the 2019 influenza season.
The Influenza Complications Alert Network (FluCAN) is a sentinel hospital-based surveillance program that operates at sites in all jurisdictions in Australia. Cases were defined as patients hospitalised at any of the 17 sentinel hospitals with influenza confirmed by nucleic acid detection. Data were also collected on a frequency matched control group of influenza-negative patients admitted with acute respiratory infection.
During the period 1 April to 31 October 2019 (the 2019 influenza season), there were 4,154 patients admitted with confirmed influenza to one of 17 FluCAN sentinel hospitals. Of these, 44% were elderly (≥ 65 years), 21% were children (< 16 years), 7.7% were Aboriginal and Torres Strait Islander peoples, 1.7% were pregnant and 73% had chronic comorbidities. Most admissions were due to influenza A infection (85%). Estimated vaccine coverage was 75% in the elderly, 49% in non-elderly adults with medical comorbidities, and 27% in young children (< 5 years). The estimated vaccine effectiveness in the target adult population was 42% (95% confidence interval [95% CI]: 36%, 49%).
There were a larger number of hospital admissions detected with confirmed influenza in this national observational surveillance system in 2019 than in 2018.
Downloads
References
Dyda A, Karki S, Hayen A, MacIntyre CR, Menzies R, Banks E et al. Influenza and pneumococcal vaccination in Australian adults: a systematic review of coverage and factors associated with uptake. BMC Infect Dis. 2016;16(1). doi: https://doi.org/10.1186/s12879-016-1820-8.
Hunt G. Record numbers of Australians getting vaccinated against the flu. [Internet.] Canberra: Greg Hunt, Federal Member for Flinders / Minister for Health and Aged Care; 29 May 2019. Available from: https://www.greghunt.com.au/record-numbers-of-australians-getting-vaccinated-against-the-flu/.
Doyle JD, Chung JR, Kim SS, Gaglani M, Raiyani C, Zimmerman RK et al. Interim estimates of 2018–19 seasonal influenza vaccine effectiveness — United States, February 2019. MMWR Morb Mortal Wkly Rep. 2019;68(6):135–9.
Kissling E, Rose A, Emborg HD, Gherasim A, Pebody R, Pozo F et al. Interim 2018/19 influenza vaccine effectiveness: six European studies, October 2018 to January 2019. Euro Surveill. 2019;24(8). doi: https://doi.org/10.2807/1560-7917.ES.2019.24.1900121.
Skowronski DM, Leir S, Sabaiduc S, Murti M, Dickinson JA, Olsha R et al. Interim estimates of 2018/19 vaccine effectiveness against influenza A(H1N1)pdm09, Canada, January 2019. Euro Surveill. 2019;24(4). doi: https://doi.org/10.2807/1560-7917.ES.2019.24.4.1900055.
Kostova D, Reed C, Finelli L, Cheng PY, Gargiullo PM, Shay DK et al. Influenza illness and hospitalizations averted by influenza vaccination in the United States, 2005–2011. PLoS One. 2013;8(6). doi: https://doi.org/10.1371/journal.pone.0066312.
Jackson ML, Phillips CH, Benoit J, Jackson LA, Gaglani M, Murthy K et al. Burden of medically attended influenza infection and cases averted by vaccination – United States, 2013/14 through 2015/16 influenza seasons. Vaccine. 2018;36(4):467–72.
Machado A, Mazagatos C, Dijkstra F, Kislaya I, Gherasim A, McDonald SA et al. Impact of influenza vaccination programmes among the elderly population on primary care, Portugal, Spain and the Netherlands: 2015/16 to 2017/18 influenza seasons. Euro Surveill. 2019;24(45). doi: https://doi.org/10.2807/1560-7917.ES.2019.24.45.1900268.
Cheng AC, Holmes M, Dwyer DE, Irving LB, Korman TM, Senenayake S et al. Influenza epidemiology in patients admitted to sentinel Australian hospitals in 2015: the Influenza Complications Alert Network. Commun Dis Intell Q Rep. 2016;40(4):E521–6.
Nation ML, Moss R, Spittal MJ, Kotsimbos T, Kelly PM, Cheng AC. Influenza vaccine effectiveness against influenza-related mortality in Australian hospitalized patients: a propensity score analysis. Clin Infect Dis. 2020;72(1):99–107.
Butler CC, van der Velden AW, Bongard E, Saville BR, Holmes J, Coenen S et al. Oseltamivir plus usual care versus usual care for influenza-like illness in primary care: an open-label, pragmatic, randomised controlled trial. Lancet. 2020;395(10217):42–52.
Muthuri SG, Venkatesan S, Myles PR, Leonardi-Bee J, Al Khuwaitir TSA, Al Mamun A et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med. 2014;2(5):395–404.
Barr IG, Deng YM, Grau ML, Han AX, Gilmour R, Irwin M et al. Intense interseasonal influenza outbreaks, Australia, 2018/19. Euro Surveill. 2019;24(33). doi: https://doi.org/10.2807/1560-7917.ES.2019.24.33.1900421.
Ainslie KEC, Shi M, Haber M, Orenstein WA. On the bias of estimates of influenza vaccine effectiveness from test-negative studies. Vaccine. 2017;35(52):7297–301.
Lewnard JA, Tedijanto C, Cowling BJ, Lipsitch M. Measurement of vaccine direct effects under the test-negative design. Am J Epidemiol. 2018;187(12):2686–97.
Published
How to Cite
License
Copyright (c) 2022 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
